One study was analyzed for the p53 genotype in patients with advanced NSCLC who had received neoadjuvant chemotherapy and found that the presence of a mutant p53 genotype was highly indicative of resistance to induction chemotherapy (P<0.002) (66). This evidence concerns the gene TP53 and non-small cell lung carcinoma.